NUTEX HEALTH REPORTS SEPTEMBER 30, 2025 THIRD QUARTER AND YEAR-TO-DATE FINANCIAL RESULTS
Rhea-AI Summary
Nutex Health (NASDAQ: NUTX) reported strong results for the three and nine months ended September 30, 2025, driven by the hospital division and arbitration recoveries. Nine‑month revenue was $723.6M, up 225.5% versus 2024, with hospital revenue of $700.5M (up 251.4%). Net income attributable to Nutex Health was $59.0M for nine months versus a $9.5M loss in 2024. EBITDA was $142.9M and Adjusted EBITDA was $243.0M for nine months. Cash and cash equivalents totaled $166.0M and net cash from operating activities was $177.7M for the nine months. The company noted substantial stock‑based compensation of $119.6M and significant reliance on IDR arbitration recoveries (≈66% of hospital revenue for nine months).
Positive
- Total revenue +225.5% to $723.6M (nine months)
- Hospital revenue +251.4% to $700.5M (nine months)
- Net income attributable to NUTX $59.0M (nine months)
- Adjusted EBITDA $243.0M (nine months)
- Net cash from operations $177.7M (nine months)
- Cash and cash equivalents $166.0M at Sept 30, 2025
Negative
- Stock-based compensation $119.6M (nine months)
- 66.1% of hospital revenue tied to IDR/arbitration recoveries
- Accounts receivable increased to $387.4M at Sept 30, 2025
- Accrued arbitration expenses $64.3M at Sept 30, 2025
News Market Reaction
On the day this news was published, NUTX gained 13.09%, reflecting a significant positive market reaction. Argus tracked a peak move of +30.6% during that session. Our momentum scanner triggered 31 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $129M to the company's valuation, bringing the market cap to $1.12B at that time. Trading volume was elevated at 2.1x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
-
Total revenue of
$723.6 million $222.3 million 225.5% -
Net income attributable to Nutex Health Inc. of
$59.0 million $9.5 million $68.5 million -
Diluted income per share of
$8.87 $1.91 -
EBITDA of
$142.9 million $19.9 million 616.4% -
Adjusted EBITDA of
$243.0 million $16.1 million 1408.6% -
Net cash from operating activities of
$177.7 million
Financial highlights for the three months ended September 30, 2025:
- Total revenue increased
$189.0 million $267.8 million $78.8 million 239.9% . The hospital division drove most of this growth, generating$260.2 million 262.8% from$71.7 million 208.9% in 2025 compared to 2024. - Of the
$260.2 million $182.1 million 70.0% ) related to a combination of both higher acuity claims as well as success through the Independent Dispute Resolution (IDR) process. - With regard to arbitration-related revenue: due to the continual underpayment from payors, we have continued to submit between 60
-70% of our visits through the IDR process, we have won a legal determination on over85% of the claims submitted, and we currently have an average collection rate of over80% of the legal determination wins. - Arbitration costs approximate 24
-26% of the arbitration related revenue. - Total stock-based compensation expense for the three months ended September 30, 2025 was
$13.2 million $2.0 million 99.5% of total stock-based compensation expense of$13.2 million - Operating income for the three months ended September 30, 2025 was
$130.4 million $9.7 million $120.7 million - Net income attributable to Nutex Health for the three months ended September 30, 2025 of
$55.4 million $8.8 million $55.4 million $13.2 million $8.8 million $2.0 million - EBITDA attributable to Nutex Health of
$91.8 million $4.3 million 2014.0% . - Adjusted EBITDA attributable to Nutex Health of
$98.5 million $9.7 million - Total visits at the Hospital Division were 46,232 for the three months ended September 30, 2025, as compared to 41,668 for the same period in 2024, an increase of 4,564 or
11.0% . Visits at mature hospitals decreased by0.6% in the three months ended September 30, 2025 as compared to the same period in 2024. - Net cash from operating activities of
$99.5 million - As of September 30, 2025, the Company had total assets of
$964.5 million $166.0 million $25.6 million
Financial highlights for the nine months ended September 30, 2025:
- Total revenue increased
$501.2 million $723.6 million $222.3 million 225.5% . The hospital division drove most of this growth, generating$700.5 million 251.4% from$199.4 million 200.0% in 2025 compared to 2024. - Of the
$700.5 million $462.9 million 66.1% ) related to a combination of both higher acuity claims as well as success through the IDR process. - With regard to arbitration-related revenue: due to the continual underpayment from payors, we have continued to submit between 60
-70% of our visits through the IDR process, we have won a legal determination on over85% of the claims submitted, and we currently have an average collection rate of over80% of the legal determination wins. - Arbitration costs approximate 24
-26% of the arbitration related revenue. - Total stock-based compensation expense for the nine months ended September 30, 2025 was
$119.6 million $2.0 million 99.5% of total stock-based compensation expense of$119.6 million - Operating income for the nine months ended September 30, 2025 was
$244.7 million $16.4 million $228.3 million - Net income attributable to Nutex Health for the nine months ended September 30, 2025 of
$59.0 million $9.5 million $59.0 million $119.6 million $9.5 million $2.0 million - EBITDA attributable to Nutex Health of
$142.9 million $19.9 million 616.4% . - Adjusted EBITDA attributable to Nutex Health of
$243.0 million $16.1 million - Total visits at the Hospital Division were 140,074 for the nine months ended September 30, 2025, as compared to 122,944 for the same period in 2024, an increase of 17,130 or
13.9% . Visits at mature hospitals increased by1.8% in the nine months ended September 30, 2025 as compared to the same period in 2024. - Net cash from operating activities of
$177.7 million
Note: EBITDA and Adjusted EBITDA are non-GAAP financial metrics. A reconciliation of non-GAAP to GAAP measures is included below in this earnings release.
"We are continuing to add to a record year with
"We are very pleased to deliver another successful and profitable quarter. With the audit revisions and related activities behind us, our team is fully focused on driving future growth both within existing operations and through new facilities. Our pipeline remains strong, reflecting continued demand for small hospitals across the country," stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health.
For more details on the Company's financial results for the three and nine months ended September 30, 2025, please refer to our Quarterly Report on Form 10-Q filed with the
Nutex Health Inc. Regains Nasdaq Compliance
On November 19, 2025 Nutex received a letter from Nasdaq Listing Qualifications confirming that the Company has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic reports with the Securities and Exchange Commission.
The letter states that following the Company's filing of its Form 10-Q for the period ended June 30, 2025 on November 18, 2025, Nasdaq has determined that Nutex Health Inc. now complies with the rule and that the matter is closed.
No further action is required by the Company in connection with this matter.
Conference Call on Restated 2024 and First Three Quarters of 2025 Results
The Company will host a conference call on Tuesday, December 2, 2025 at 10:30 a.m. ET to discuss its restated fiscal year 2024 results and its results for the first three quarters of 2025.
Participant Listening: 1-877-407-9208 or 1-201-493-6784
Participant Link: https://callme.viavid.com/viavid/?callme=true&passcode=13746493&h=true&info=company&r=true&B=6
To access the call, please dial in approximately five minutes before start time. Those who are unable to attend the live conference call may access the recording on the Company's website.
|
NUTEX HEALTH INC. |
||||
|
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) |
||||
|
|
||||
|
(In thousands, except share and per share amounts) |
|
September 30, |
|
December 31, |
|
Assets |
|
|
|
|
|
Current assets: |
|
|
|
|
|
Cash and cash equivalents |
|
$ 166,048 |
|
$ 40,640 |
|
Restricted short-term investments |
|
— |
|
2,941 |
|
Accounts receivable |
|
387,409 |
|
232,449 |
|
Accounts receivable - related parties |
|
7,353 |
|
3,602 |
|
Inventories |
|
3,158 |
|
2,850 |
|
Income tax receivable |
|
12,097 |
|
— |
|
Prepaid expenses and other current assets |
|
16,586 |
|
9,997 |
|
Total current assets |
|
592,651 |
|
292,479 |
|
Property and equipment, net |
|
82,821 |
|
77,933 |
|
Operating lease right-of-use assets |
|
27,354 |
|
27,872 |
|
Financing lease right-of-use assets |
|
225,719 |
|
218,889 |
|
Intangible assets, net |
|
21,555 |
|
15,530 |
|
Goodwill, net |
|
13,919 |
|
13,919 |
|
Deferred tax assets |
|
— |
|
7,987 |
|
Other assets |
|
499 |
|
711 |
|
Total assets |
|
$ 964,518 |
|
$ 655,320 |
|
Liabilities and Equity |
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
Accounts payable |
|
$ 45,475 |
|
$ 9,614 |
|
Accounts payable - related parties |
|
4,082 |
|
806 |
|
Lines of credit |
|
5,304 |
|
3,554 |
|
Current portion of long-term debt |
|
18,004 |
|
14,395 |
|
Operating lease liabilities, current portion |
|
2,111 |
|
2,080 |
|
Financing lease liabilities, current portion |
|
7,108 |
|
7,705 |
|
Accrued arbitration expenses |
|
64,313 |
|
47,742 |
|
Accrued income tax expense |
|
— |
|
26,533 |
|
Accrued stock-based compensation |
|
11,194 |
|
16,356 |
|
Accrued expenses and other current liabilities |
|
27,865 |
|
25,440 |
|
Total current liabilities |
|
185,456 |
|
154,225 |
|
Long-term debt, net |
|
25,574 |
|
22,466 |
|
Operating lease liabilities, net |
|
30,423 |
|
30,617 |
|
Financing lease liabilities, net |
|
270,077 |
|
259,479 |
|
Deferred tax liabilities |
|
14,955 |
|
— |
|
Total liabilities |
|
526,485 |
|
466,787 |
|
|
|
|
|
|
|
Commitments and contingencies (Note 10) |
|
|
|
|
|
Equity: |
|
|
|
|
|
Common stock, |
|
7 |
|
6 |
|
Additional paid-in capital |
|
615,180 |
|
489,409 |
|
Accumulated deficit |
|
(298,021) |
|
(356,976) |
|
Nutex Health Inc. equity |
|
317,166 |
|
132,439 |
|
Noncontrolling interests |
|
120,867 |
|
56,094 |
|
Total equity |
|
438,033 |
|
188,533 |
|
Total liabilities and equity |
|
$ 964,518 |
|
$ 655,320 |
|
NUTEX HEALTH INC. |
||||||||
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) |
||||||||
|
|
||||||||
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
||||
|
(In thousands, except share and per share amounts) |
|
2025 |
|
2024 |
|
2025 |
|
2024 |
|
Revenue: |
|
|
|
|
|
|
|
|
|
Hospital division |
|
$ 260,239 |
|
$ 71,733 |
|
$ 700,488 |
|
$ 199,367 |
|
Population health management division |
|
7,565 |
|
7,062 |
|
23,090 |
|
22,964 |
|
Total revenue |
|
267,804 |
|
78,795 |
|
723,578 |
|
222,331 |
|
|
|
|
|
|
|
|
|
|
|
Operating costs and expenses: |
|
|
|
|
|
|
|
|
|
Payroll |
|
38,817 |
|
29,848 |
|
109,961 |
|
85,249 |
|
Contract services |
|
53,837 |
|
11,657 |
|
153,601 |
|
32,482 |
|
Medical supplies |
|
3,307 |
|
3,983 |
|
11,920 |
|
12,894 |
|
Depreciation and amortization |
|
5,003 |
|
4,972 |
|
15,343 |
|
13,691 |
|
Other |
|
11,959 |
|
6,418 |
|
34,610 |
|
23,380 |
|
Total operating costs and expenses |
|
112,923 |
|
56,878 |
|
325,435 |
|
167,696 |
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
154,881 |
|
21,917 |
|
398,143 |
|
54,635 |
|
|
|
|
|
|
|
|
|
|
|
Corporate and other costs: |
|
|
|
|
|
|
|
|
|
Stock-based compensation |
|
13,217 |
|
1,964 |
|
119,606 |
|
1,952 |
|
Impairment of assets |
|
— |
|
425 |
|
— |
|
3,899 |
|
Impairment of goodwill |
|
— |
|
— |
|
— |
|
3,197 |
|
General and administrative expenses |
|
11,297 |
|
9,865 |
|
33,830 |
|
29,175 |
|
Total corporate and other costs |
|
24,514 |
|
12,254 |
|
153,436 |
|
38,223 |
|
|
|
|
|
|
|
|
|
|
|
Operating income |
|
130,367 |
|
9,663 |
|
244,707 |
|
16,412 |
|
|
|
|
|
|
|
|
|
|
|
Interest expense, net |
|
5,452 |
|
5,381 |
|
17,250 |
|
14,880 |
|
Loss on warrant liability |
|
— |
|
6,734 |
|
— |
|
1,073 |
|
Other (income) expense |
|
976 |
|
128 |
|
8,570 |
|
(711) |
|
Income (loss) before taxes |
|
123,939 |
|
(2,580) |
|
218,887 |
|
1,170 |
|
|
|
|
|
|
|
|
|
|
|
Income tax expense |
|
27,140 |
|
4,585 |
|
55,138 |
|
5,868 |
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
96,799 |
|
(7,165) |
|
163,749 |
|
(4,698) |
|
|
|
|
|
|
|
|
|
|
|
Less: net income attributable to noncontrolling interests |
|
41,364 |
|
1,623 |
|
104,794 |
|
4,819 |
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to Nutex Health Inc. |
|
$ 55,435 |
|
$ (8,788) |
|
$ 58,955 |
|
$ (9,517) |
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) per common share |
|
|
|
|
|
|
|
|
|
Basic |
|
$ 8.27 |
|
$ (1.72) |
|
$ 9.63 |
|
$ (1.91) |
|
Diluted |
|
$ 7.76 |
|
$ (1.72) |
|
$ 8.87 |
|
$ (1.91) |
|
NUTEX HEALTH INC. |
||||
|
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) |
||||
|
|
||||
|
|
|
Nine Months Ended September 30, |
||
|
(In thousands) |
|
2025 |
|
2024 |
|
Cash flows from operating activities: |
|
|
|
|
|
Net income |
|
$ 163,749 |
|
$ (4,698) |
|
Adjustment to reconcile net income to net cash from operating activities: |
|
|
|
|
|
Depreciation and amortization |
|
15,343 |
|
13,691 |
|
Loss on warrant liability |
|
— |
|
1,073 |
|
Impairment of assets |
|
— |
|
3,899 |
|
Impairment of goodwill |
|
— |
|
3,197 |
|
Derecognition of goodwill |
|
— |
|
453 |
|
Stock-based compensation expense |
|
119,606 |
|
1,952 |
|
Changes to deferred taxes |
|
22,942 |
|
(1,743) |
|
Debt accretion expense |
|
756 |
|
805 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
(Increase)/Decrease in Accounts receivable |
|
(154,960) |
|
(4,253) |
|
(Increase)/Decrease in Accounts receivable - related party |
|
(3,751) |
|
550 |
|
(Increase)/Decrease in Inventories |
|
(308) |
|
1,131 |
|
(Increase)/Decrease in Income tax receivable |
|
(12,097) |
|
— |
|
(Increase)/Decrease in Prepaid expenses and other current assets |
|
(6,376) |
|
(1,361) |
|
(Increase)/Decrease in Operating right-of-use assets |
|
518 |
|
411 |
|
Increase/(Decrease) in Accounts payable |
|
36,637 |
|
(7,975) |
|
Increase/(Decrease) in Accounts payable - related party |
|
3,276 |
|
(39) |
|
Increase/(Decrease) in Operating lease liabilities |
|
(164) |
|
(692) |
|
Increase/(Decrease) in Accrued arbitration expenses |
|
16,571 |
|
— |
|
Increase/(Decrease) in Accrued income tax expense |
|
(26,533) |
|
— |
|
Increase/(Decrease) in Accrued expenses and other current liabilities |
|
2,527 |
|
16,698 |
|
Net cash provided by operating activities |
|
177,736 |
|
23,099 |
|
|
|
|
|
|
|
Cash flows from investing activities: |
|
|
|
|
|
Acquisitions of property and equipment |
|
(1,117) |
|
(1,909) |
|
Proceeds from restricted short-term investment |
|
2,941 |
|
— |
|
Cash related to sale of business |
|
— |
|
(361) |
|
Cash related to asset acquisition |
|
(1,994) |
|
— |
|
Net cash used in investing activities |
|
(170) |
|
(2,270) |
|
|
|
|
|
|
|
Cash flows from financing activities: |
|
|
|
|
|
Proceeds from lines of credit |
|
5,043 |
|
1,132 |
|
Proceeds from notes payable |
|
273 |
|
7,015 |
|
Repayments of lines of credit |
|
(3,293) |
|
(1,119) |
|
Repayments of notes payable |
|
(8,319) |
|
(8,332) |
|
Repayments of finance leases |
|
(4,004) |
|
(1,924) |
|
Proceeds from common stock issuance, net issuance costs |
|
— |
|
9,202 |
|
Proceeds from exercise of warrants |
|
— |
|
801 |
|
Members' contributions |
|
316 |
|
961 |
|
Members' distributions |
|
(42,174) |
|
(3,659) |
|
Net cash provided by (used in) financing activities |
|
(52,158) |
|
4,077 |
|
Net increase in cash and cash equivalents |
|
125,408 |
|
24,906 |
|
Cash and cash equivalents - beginning of the period |
|
40,640 |
|
22,002 |
|
Cash and cash equivalents - end of the period |
|
$ 166,048 |
|
$ 46,908 |
Non-GAAP Financial Measures (Unaudited)
EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA are used as a supplemental non-GAAP financial measure by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. We believe EBITDA and Adjusted EBITDA are useful because it allows us to more effectively evaluate our operating performance.
We define EBITDA as net income (loss) attributable to Nutex Health Inc. plus interest expense, income taxes, depreciation and amortization.
We define Adjusted EBITDA as net income (loss) attributable to Nutex Health Inc. plus net interest expense, income taxes, depreciation and amortization, further adjusted for stock-based compensation, certain defined items of expense and any acquisition-related costs and impairments. Interest expense includes interest on lease liabilities, which is a component of total finance lease cost. A reconciliation of net loss to Adjusted EBITDA is included below.
Beginning in the first quarter of 2025, we have updated our presentation of Adjusted EBITDA to separately disclose finance lease payments related to leases under ASC 842. We believe this change provides greater transparency into our operating performance.
Adjusted EBITDA is not intended to serve as an alternative to
|
|
Three Months Ended September 30, |
||||||
|
|
2025 |
|
2024 |
||||
|
Reconciliation of net income (loss) attributable to Nutex |
(Updated) |
|
(Prior) |
|
(Updated) |
|
(Prior) |
|
Net income (loss) attributable to Nutex Health Inc. |
$ 55,435 |
|
$ 55,435 |
|
$ (8,788) |
|
$ (8,788) |
|
Depreciation and amortization |
5,003 |
|
5,003 |
|
4,972 |
|
4,972 |
|
Interest expense, net |
5,452 |
|
5,452 |
|
5,381 |
|
5,381 |
|
Income tax expense |
27,140 |
|
27,140 |
|
4,585 |
|
4,585 |
|
Allocation to noncontrolling interests |
(1,243) |
|
(1,243) |
|
(1,808) |
|
(1,808) |
|
EBITDA |
91,787 |
|
91,787 |
|
4,342 |
|
4,342 |
|
Loss on warrant liability |
— |
|
— |
|
6,734 |
|
6,734 |
|
Impairment of assets |
— |
|
— |
|
424 |
|
424 |
|
Finance lease payments(1) |
(6,474) |
|
— |
|
(3,794) |
|
— |
|
Stock-based compensation |
13,217 |
|
13,217 |
|
1,964 |
|
1,964 |
|
Adjusted EBITDA |
$ 98,530 |
|
$ 105,004 |
|
$ 9,670 |
|
$ 13,464 |
|
|
Nine Months Ended September 30, |
||||||
|
|
2025 |
|
2024 |
||||
|
Reconciliation of net income (loss) attributable to Nutex |
(Updated) |
|
(Prior) |
|
(Updated) |
|
(Prior) |
|
Net income (loss) attributable to Nutex Health Inc. |
$ 58,955 |
|
$ 58,955 |
|
$ (9,517) |
|
$ (9,517) |
|
Depreciation and amortization |
15,343 |
|
15,343 |
|
13,691 |
|
13,691 |
|
Interest expense, net |
17,250 |
|
17,250 |
|
14,880 |
|
14,880 |
|
Income tax expense |
55,138 |
|
55,138 |
|
5,868 |
|
5,868 |
|
Allocation to noncontrolling interests |
(3,815) |
|
(3,815) |
|
(4,980) |
|
(4,980) |
|
EBITDA |
142,871 |
|
142,871 |
|
19,942 |
|
19,942 |
|
Loss on warrant liability |
— |
|
— |
|
1,073 |
|
1,073 |
|
Impairment of assets |
— |
|
— |
|
3,898 |
|
3,898 |
|
Impairment of goodwill |
— |
|
— |
|
3,197 |
|
3,197 |
|
Finance lease payments(1) |
(19,512) |
|
— |
|
(13,957) |
|
— |
|
Stock-based compensation |
119,606 |
|
119,606 |
|
1,952 |
|
1,952 |
|
Adjusted EBITDA |
$ 242,965 |
|
$ 262,477 |
|
$ 16,105 |
|
$ 30,062 |
|
|
|
|
(1) |
Finance lease payments consist of cash payments for financing leases under ASC 842, which should be deducted from EBITDA. We believe this change is useful to investors to evaluate the ongoing operating performance of our business. |
About Nutex Health Inc.
Headquartered in
The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 24 facilities in 11 states.
The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups.
Forward-Looking Statements
Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will", "will likely result" "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2025 under the heading "Risk Factors" in Part II, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.
View original content:https://www.prnewswire.com/news-releases/nutex-health-reports-september-30-2025-third-quarter-and-year-to-date-financial-results-302620892.html
SOURCE Nutex Health, Inc.
FAQ
What were Nutex Health (NUTX) total revenues for the nine months ended September 30, 2025?
How much net income did Nutex Health (NUTX) report for the first nine months of 2025?
What is Nutex Health's (NUTX) Adjusted EBITDA for the first nine months of 2025?
How much cash did Nutex Health (NUTX) hold as of September 30, 2025?
What portion of Nutex Health (NUTX) hospital revenue for nine months 2025 came from arbitration/IDR recoveries?
Did Nutex Health (NUTX) generate positive operating cash flow in 2025?
